Murat Can Cobanoglu received his B.Sc. in Computer Science & Engineering (major) & Mathematics (minor) in 2008 from Sabanci University, and his M.Sc. in Computer Science & Engineering in 2010 also from Sabanci University. He received his Ph.D. in Computational Biology in 2015 from the Carnegie Mellon University - University of Pittsburgh Joint Ph.D. Program in Computational Biology. He studied the use of machine learning to make a small number of accurate drug predictions to then be experimentally validated under the joint mentorship of Lans Taylor and Ivet Bahar. He then had a brief start-up experience at the CMU incubator space Project Olympus with a Ph.D. classmate, Aaron Wise. Afterwards, he moved to UT Southwestern as the inaugural UT Southwestern Distinguished Fellow to pursue an independent research agenda. The goal of his lab is to build a computational pipeline to predict a small number of targeted cancer therapeutics which can then be validated in advanced clinically relevant assays such as 3D in vitro systems or ex vivo human tumors. The UT Southwestern Office for Technology Development has recently (in 2020) filed two provisional patent applications based on his work, one for a melanoma drug candidate and another for an ER+ breast cancer drug candidate.


Graduate School
Sabanci University (2010), Computer Sciences
Graduate School
Carnegie-Mellon University (2015), Computational Biology

Research Interest

  • Bioimage informatics
  • Cancer
  • Drug discovery
  • Machine learning
  • Single cell RNA/protein expression analysis


Featured Publications LegendFeatured Publications

The present and future role of artificial intelligence and machine learning in anesthesiology.
Alexander JC, Romito BT, Çobanoglu MC, Int Anesthesiol Clin 2020 Aug
An analog of glibenclamide selectively enhances autophagic degradation of misfolded a1-antitrypsin Z.
Wang Y, Cobanoglu MC, Li J, Hidvegi T, Hale P, Ewing M, Chu AS, Gong Z, Muzumdar R, Pak SC, Silverman GA, Bahar I, Perlmutter DH PLoS ONE 2019 14 1 e0209748
Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington's Disease Model through the Application of Quantitative Systems Pharmacology.
Pei F, Li H, Henderson MJ, Titus SA, Jadhav A, Simeonov A, Cobanoglu MC, Mousavi SH, Shun T, McDermott L, Iyer P, Fioravanti M, Carlisle D, Friedlander RM, Bahar I, Taylor DL, Lezon TR, Stern AM, Schurdak ME Sci Rep 2017 Dec 7 1 17803
BalestraWeb: efficient online evaluation of drug-target interactions.
Cobanoglu MC, Oltvai ZN, Taylor DL, Bahar I Bioinformatics 2015 Jan 31 1 131-3
Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and Cocaine Binding.
Cheng MH, Block E, Hu F, Cobanoglu MC, Sorkin A, Bahar I Front Neurol 2015 6 134
A genome-wide RNAi screen identifies potential drug targets in a C. elegans model of a1-antitrypsin deficiency.
O'Reilly LP, Long OS, Cobanoglu MC, Benson JA, Luke CJ, Miedel MT, Hale P, Perlmutter DH, Bahar I, Silverman GA, Pak SC Hum. Mol. Genet. 2014 Oct 23 19 5123-32
Ionizing irradiation protection and mitigation of murine cells by carbamazepine is p53 and autophagy independent.
Kim H, Bernard ME, Farkas A, Goff J, Kalash R, Houghton F, Shields D, Franicola D, Dixon T, Zhang X, Epperly M, Wang H, Cobanoglu MC, Greenberger JS In Vivo 2012 May-Jun 26 3 341-54